D And Suzhou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GAITHERSBURG, Md. and SUZHOU, China, June 22, 2022 /PRNewswire/ Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer, Dmitry Samarsky, PhD, will present the latest developments and expanded applications of its Dual-Targeted RNAi therapeutics based on its proprietary GalAhead technology and product pipeline, at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium. The Symposium will take place virtually on June 22-24, 2022. Sirnaomics' proprietary GalNAc-RNAi therapeutic platform, GalAhead, relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA (miniaturized RNAi triggers) and muRNA (multi-unit RNAi triggers). mxRNAs are comprised of single ~30 nt long oligonucleotides to downregulate individu ....

United States , Nigel Yip , Dmitry Samarsky , Bunny Lee , Alexis Feinberg , Patrick Lu , Sirnaomics Ltd , Prnewswire Sirnaomics Ltd , Company Or Sirnaomics , Chief Technology Officer , From Concept , Executive Director , Technology Officer , Financial Officer , Media Contact , D And Suzhou , June 22 , 022 Prnewswire Sirnaomics Ltd The Quot Company Or , Tock Code 2257 Hk , A Leading Biopharmaceutical Company In Discovery And Development Of Rnai Therapeutics , Nnounced That The Company 39s Chief Technology Officer , Dmitry Samarsky , Ill Present The Latest Developments And Expanded Applications Of Its Dual Targeted Rnai Therapeutics Based On Proprietary Galahead Technology Product Pipeline , T The 4th Annual Rna Therapeutic From Concept To Clinic Symposium Will Take Place Virtually On June 22 24 , 022 Sirnaomics 39 Proprietary Galnac Rnai Therapeutic Platform , Elies On Unique Rna Structures That Allow The Knockdown Of Single Or Multiple Distinct Mrna Targets ,